small molecule glp-1 receptor agonist How Agonists Evolved from Diabetes to Weight Loss Treatments Orforglipron, an Oral Small-Molecule GLP-1

Epub 2009 Mar 24

[2] Compounded versions are often more affordable, but they are not FDA approved

Morgan GLP-1 supply is expected to increase across the globe GLP-1 penetration remains low globally, with roughly 7% of diabetes patients and 2% of the obese population currently using these medications

Native OXM invokes a dual component pathway to glucose lowering, a direct weight-loss independent component that has an acute onset, and an indirect component via weight loss that has a more gradual onset and protracted time course profile which has been shown in obese humans with and without diabetes [17]

The category has also gained global attention for its weight-loss benefits

Asia Pacific is emerging as the fastest-growing region, driven by rising rates of type 2 diabetes, urban obesity, and expanding healthcare access